Business Context and Reporting Period
This Form 8-K was filed by Halozyme Therapeutics, Inc. on February 5, 2007. The report discloses the Board of Directors' approval of annual cash and equity bonuses for senior management for the 2006 fiscal year, as well as the establishment of annual base salaries for 2007.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation details.
| Executive | Title | 2006 Cash Bonus | 2006 Equity Bonus (Options) | 2007 Base Salary |
|---|---|---|---|---|
| Jonathan E. Lim | President and CEO | $53,550 | 39,603 shares | $360,000 |
| Robert Little | Chief Commercial Officer | $21,750 | 10,861 shares | $307,400 |
| Richard Yocum | VP-Clinical Development | $36,000 | 17,976 shares | $270,000 |
| Gregory I. Frost | Chief Scientific Officer | $31,500 | 15,729 shares | $265,000 |
| William Fallon | VP-Manufacturing and Operations | $0 | 0 shares | $260,000 |
| David A. Ramsay | Chief Financial Officer | $25,650 | 12,943 shares | $235,000 |
| Don A. Kennard | VP-Regulatory Affairs | $30,000 | 14,980 shares | $214,000 |
Note: Equity bonuses are incentive stock options with an exercise price of $7.51 per share. Vesting begins one-third on February 5, 2008, with the remainder vesting monthly.
Material Changes
The filing does not report material changes in financial performance compared to prior periods. It details the specific compensation adjustments for 2007 salaries and the payout of 2006 performance bonuses.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of risks and contingencies. Management commentary is limited to the criteria used for bonus determination, which included individual performance and the Company's operational, clinical, and financial performance during 2006.
Key Facts for Investor Verification
- Compensation Structure: Verify the total cash and equity cost of the approved 2006 bonuses and 2007 salaries against the company's cash reserves.
- Option Terms: Confirm the vesting schedule (1/3 cliff vesting in 2008, then monthly) and the $7.51 exercise price for the granted options.
- Eligibility Exceptions: Note that William Fallon received no 2006 bonus due to a late 2006 start date, and Robert Little's bonus was prorated.
- Performance Criteria: The filing states bonuses were based on operational, clinical, and financial performance, but does not quantify these metrics.